StreetInsider.com News Articles

Form SCHEDULE 13G/A Annexon, Inc. Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260727/26819965.html

Form SCHEDULE 13G/A Annexon, Inc. Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260727/26819965.html

Citizens Starts Annexon Biosciences (ANNX) at Market Underperform

Tue, 21 Jul 2026 03:46:34 -0400

Citizens analyst Jonathan Wolleben initiates coverage on Annexon Biosciences (NASDAQ: ANNX) with a Market Underperform rating and a price target of $3.00.

The analyst comments: “We initiate coverage on Annexon Biosciences with a Market Underperform rating and a $3 risk-adjusted, DCF-derived price target. ANNX is developing first-in-class C1q inhibitors targeting the initiating step of the classical complement cascade across ophthalmology, neurology, and autoimmune diseases. Investor focus is on vonaprument, which is in Phase 3 for geographic atrophy (GA), while the clinical pipeline also includes tanruprubart for Guillain-Barré syndrome (GBS) and ANX1502 for cold agglutinin disease (CAD). We think the top-line Phase

Citizens Starts Annexon Biosciences (ANNX) at Market Underperform

Tue, 21 Jul 2026 03:46:34 -0400

Citizens analyst Jonathan Wolleben initiates coverage on Annexon Biosciences (NASDAQ: ANNX) with a Market Underperform rating and a price target of $3.00.

H.C. Wainwright Reiterates Buy Rating on Annexon Biosciences (ANNX)

Mon, 20 Jul 2026 06:50:38 -0400

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $14.00 price target on Annexon Biosciences (NASDAQ: ANNX).

The analyst commented: "There are two key findings from the baseline analyses from ARCHER data shared at the ASRS 2026, which we think are supportive of ARCHER II's design. We think the data confirmed 15-letter loss events (n=27) clustered tightly in patients with baseline BCVA between nearly 44 and nearly 69 letters. No events occurred in patients with baseline BCVA below 44 letters, given that they simply had too little vision to lose 15 letters. Events also declined in patients above 69 letters,

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Thu, 16 Jul 2026 16:05:00 -0400

BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on July 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the two new non-executive employees received options to purchase 335,000 shares of Annexon common stock. The options carry a ten-year

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Thu, 16 Jul 2026 16:05:00 -0400

In the aggregate, the two new non-executive employees received options to purchase 335,000 shares of Annexon common stock. The options carry a ten-year

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Thu, 16 Jul 2026 16:05:00 -0400

In the aggregate, the two new non-executive employees received options to purchase 335,000 shares of Annexon common stock. The options carry a ten-year

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Thu, 16 Jul 2026 16:05:00 -0400

In the aggregate, the two new non-executive employees received options to purchase 335,000 shares of Annexon common stock. The options carry a ten-year

Form 144 Annexon, Inc. Filed by: WIGGANS THOMAS G

Wed, 15 Jul 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260715/26774384.html

Form 144 Annexon, Inc. Filed by: WIGGANS THOMAS G

Wed, 15 Jul 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260715/26774384.html

Annexon Biosciences (ANNX) PT Raised to $25 at Needham

Wed, 15 Jul 2026 07:28:12 -0400

(Updated - July 15, 2026 7:28 AM EDT)

Needham analyst Joseph Stringer raised the price target on Annexon Biosciences (NASDAQ: ANNX) to $25.00 (from $11.00) while maintaining a Buy rating.

The analyst commented: "ANNX plans to announce topline data in 4Q26 from the pivotal Ph3 ARCHER II trial evaluating vonaprument in patients with geographic atrophy (GA), and we view the readout as a significant and binary event for the stock. In this deep dive preview note, we: 1) walk through in detail the Ph2 data and Ph3 setup; 2) provide takeaways from our doc call on 7/9/26 w/ Dr. David Eichenbaum, an

Annexon Biosciences (ANNX) PT Raised to $25 at Needham

Wed, 15 Jul 2026 07:28:12 -0400

(Updated - July 15, 2026 7:28 AM EDT)

Needham analyst Joseph Stringer raised the price target on Annexon Biosciences (NASDAQ: ANNX) to $25.00 (from $11.00) while maintaining a Buy rating.

Annexon to present Phase 2 GA trial data at ASRS 2026 meeting

Tue, 14 Jul 2026 16:05:26 -0400

Annexon, Inc. (NASDAQ: ANNX) announced it will deliver an oral presentation at the American Society of Retina Specialists 44th Annual Scientific Meeting, held July 15–18, 2026, in Montréal, Québec, Canada.

The presentation will highlight findings from the completed Phase 2 ARCHER trial of vonaprument, an investigational antigen-binding fragment designed to inhibit C1q, a molecule involved in the classical complement pathway. The drug is being studied as a treatment for geographic atrophy (GA), a form of dry age-related macular degeneration.

The presentation, titled "Baseline Characteristics Associated with Loss of BCVA ≥15 ETDRS Letters in Participants with Geographic Atrophy in the Phase 2 ARCHER

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

Tue, 14 Jul 2026 16:05:00 -0400

BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced an oral presentation on the neuroprotective effect of vonaprument at the American Society of Retina Specialists (ASRS) 44^th Annual Scientific Meeting being held July 15–18, 2026 in Montréal, Québec, Canada.

In the Phase 2 ARCHER trial, vonaprument demonstrated significant vision preservation in patients with dry age-related macular degeneration (AMD) with geographic atrophy (GA). An upcoming oral presentation at ASRS will

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

Tue, 14 Jul 2026 16:05:00 -0400

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

Tue, 14 Jul 2026 16:05:00 -0400

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

Tue, 14 Jul 2026 16:05:00 -0400

Form 144 Annexon, Inc. Filed by: WIGGANS THOMAS G

Tue, 14 Jul 2026 13:56:00 -0400

si-local-file:///var/storage/secattach/20260714/26767567.html

Form 144 Annexon, Inc. Filed by: WIGGANS THOMAS G

Tue, 14 Jul 2026 13:56:00 -0400

si-local-file:///var/storage/secattach/20260714/26767567.html

Annexon Biosciences (ANNX) Reiterate at Overweight by Cantor Fitzgerald on Vonaprument

Mon, 13 Jul 2026 07:39:58 -0400

Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Annexon Biosciences (NASDAQ: ANNX).

The analyst commented, "For a neuroprotective drug, the KOL believes that including patients with both non-foveal and sub-foveal GA is important as there are photoreceptor cells alive in foveal GA and you want to preserve them, which could lead to clinical benefit. He noted that the lampalizumab data patients with sub-foveal GA lose vision faster per year than the non-foveal patients – typically an extra 1-2 letters per year. In P2 ARCHER study, with the exception of having ~50% of the patients with/without foveal GA, other baseline

Form SCHEDULE 13G/A Annexon, Inc. Filed by: Redmile Group, LLC

Wed, 08 Jul 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260708/26748842.html

Form SCHEDULE 13G/A Annexon, Inc. Filed by: Redmile Group, LLC

Wed, 08 Jul 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260708/26748842.html

Form SCHEDULE 13G/A Annexon, Inc. Filed by: FMR LLC

Wed, 08 Jul 2026 10:12:00 -0400

si-local-file:///var/storage/secattach/20260708/26745703.html

Form SCHEDULE 13G/A Annexon, Inc. Filed by: FMR LLC

Wed, 08 Jul 2026 10:12:00 -0400

si-local-file:///var/storage/secattach/20260708/26745703.html